KR970002493B1 - Process for preparing adriamycin by fermentation - Google Patents
Process for preparing adriamycin by fermentation Download PDFInfo
- Publication number
- KR970002493B1 KR970002493B1 KR1019930024430A KR930024430A KR970002493B1 KR 970002493 B1 KR970002493 B1 KR 970002493B1 KR 1019930024430 A KR1019930024430 A KR 1019930024430A KR 930024430 A KR930024430 A KR 930024430A KR 970002493 B1 KR970002493 B1 KR 970002493B1
- Authority
- KR
- South Korea
- Prior art keywords
- adriamycin
- methionine
- medium
- strain
- culture
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/44—Preparation of O-glycosides, e.g. glucosides
- C12P19/56—Preparation of O-glycosides, e.g. glucosides having an oxygen atom of the saccharide radical directly bound to a condensed ring system having three or more carbocyclic rings, e.g. daunomycin, adriamycin
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
본 발명은 발효법에 의해 항생물질 아드리아마이신을 제조하는 방법에 관한 것이며, 보다 상세하게는 엘-메티오닌 유사체에 대해 내성을 갖는 스트렙토미세스 퓨세티우스 바. 카에시우스(Streptomyces peucetiusvar. caesius) MWA-72(KFCC-10798)을 배양하여 아드리아마이신을 생산함에 있어서 배지에 엘-메티오닌을 첨가시켜 아드리아마이신의 생산성을 향상시킴을 특징으로 하는 방법에 관한 것이다.The present invention relates to a method for preparing the antibiotic adriamycin by a fermentation method, and more particularly, Streptomyces fusethius bar resistant to the L-methionine analog. In the production of adriamycin by culturing Caesius (Streptomyces peucetiusvar.caesius) MWA-72 (KFCC-10798), a method characterized by improving the productivity of adriamycin by adding L-methionine to the medium.
여러 종류의 종양 치료에 널리 사용되는 안트라사이클린 글리코사이드 항생물질인 아드리아마이신(Adriamycin) 및 다우노마이신(Daunomycin)의 생합성 과정을 살펴보면 안트라사이클리논(Amtracyclinone) 부분은 아세테이트와 프로피오네이트로부터 합성되고 (J. Am. Chem. Soc. 98, 3370, 1976 : Phytochemistey 18, 178, 1979), 메톡실기는 메티오닌에서 공급되며(Biotechnol. Lett. 1, 471, 1979 : J. Antibiot. 31, 178, 1978), 아미노당 부분은 포도당으로부터 직접 유래된다고 알려져 있다. (Antibiotiki 21, 299, 1976)In the biosynthesis process of adriamycin and daunomycin, the anthracycline glycoside antibiotics widely used in the treatment of various tumors, the anthracyclinone moiety is synthesized from acetate and propionate. (J. Am. Chem. Soc. 98, 3370, 1976: Phytochemistey 18, 178, 1979), methoxyl groups are supplied from methionine (Biotechnol. Lett. 1, 471, 1979: J. Antibiot. 31, 178, 1978 The amino sugar portion is known to be derived directly from glucose. (Antibiotiki 21, 299, 1976)
본 발명자들은 아드리아마이신의 생합성 경로에서 메티오닌이 메톡실기를 공급한다는 점에 착안하여, 공지의 아드리아마이신 생산 균주인 스트렙토미세스 퓨세티우스 바. 카에시우스 ATCC 27952를 변이시켜 엘-메티오닌 유사체에 대한 내성을 갖는 변이주를 선별하여 아드리아마이신 고생산 균주 스트렙토미세스 퓨세티우스 바. 카에시우스 MWA-72(KFCC-10798)를 개발한 바 있으며(본 출원과 동일자로 출원된 본 출원인의 특허출원 : 엘-메티오닌 유사체에 내성을 갖는 스트렙토미세스속 미생물 및 이를 이용한 아드리아마이신의 제조방법), 나아가 이 변이주의 배양중 여러 가지 아미노산을 배지에 첨가시켜 축적되는 아드리아마이신의 량을 조사한 결과, 엘-메티오닌을 첨가하였을 때 아드리아마이신의 생산성이 향상되며 첨가시기와 량을 조절하여 약 17%의 생산성을 향상시킬 수 있음을 발견하고 본 발명을 완성하기에 이르렀다.The inventors pay attention to the fact that methionine supplies methoxyl groups in the biosynthetic pathway of adriamycin, streptomyces fusethius bar, a known adriamycin producing strain. Mutation of Kaesius ATCC 27952 to select mutants that are resistant to the el-methionine analogue to adriamycin high production strain Streptomyces fusethius bar. Kaesius MWA-72 (KFCC-10798) has been developed (applicant's patent application filed with the same applicant as the present application: Streptomyces genus microorganisms resistant to the L-methionine analog and a method for producing adriamycin using the same In addition, as a result of investigating the amount of adriamycin accumulated by adding various amino acids to the medium during the culture of the mutant strain, the productivity of adriamycin is improved when L-methionine is added, and the addition time and amount are controlled to about 17%. It has been found that the productivity can be improved and the present invention has been completed.
즉, 본 발명의 목적은 스트렙토미세스 퓨세티우스 바. 카에시우스 MWA-72(KFCC-10798)을 배양하여 아드리아마이신을 축적하고 배양액으로부터 그를 회수하여 아드미아마이신을 생산하는 방법에 있어서, 배양 배지에 엘-메티오닌을 첨가함을 특징으로 하는 발효에 의해 아드리아마이신을 생산하기 위한 개량된 방법을 제공하는 것이다.In other words, an object of the present invention is Streptomyces fusethius bar. A method of culturing Kaesius MWA-72 (KFCC-10798) to accumulate adriamycin and recovering it from the culture to produce admiamycin, wherein fermentation is characterized by adding L-methionine to the culture medium. It is to provide an improved method for producing adriamycin.
이하, 본 발명을 보다 상세히 설명한다.Hereinafter, the present invention will be described in more detail.
친주인 스트렙토미세스 퓨세티우스 바. 카에시우스 ATCC 27952를 변이시켜 본 발명에서 사용하는 변이주인 스트렙토미세스 퓨세티우스 바. 카에시우스 MWA-72(KFCC-10798)을 얻는 방법은 통상의 변이방법에 의해 행할 수 있다. 즉, 친주인 스트렙토미세스 퓨세티우스 바. 카에시우스 ATCC 27952를 한천 사면배지에서 배양후 포자를 획득하고, 이 포자의 현탁액에 자외선 또는 화학적 돌연변이원을 적용하여 변이를 시킨 후 엘-메티오닌 유사체에 내성을 갖는 변이주를 선별하고 이중에서 아드리아마이신의 생산성이 높은 균주를 분리하는 것이다.Parent, Streptomyces fuseotius bar. Streptomyces fusettius bar, which is a variant strain used in the present invention by mutating Kaesius ATCC 27952. The method of obtaining Kaesius MWA-72 (KFCC-10798) can be performed by a normal mutation method. Namely, the parent strain Streptomyces fuseotius bar. After culturing Kaesius ATCC 27952 in agar medium, spores were obtained, and the suspension of the spores was mutated by applying UV or chemical mutagen, and then the mutant strains resistant to the el-methionine analog were selected and doubled adriamycin. It is to isolate a highly productive strain.
본 발명의 방법에 따라 균주를 배양하여 아드리아마이신을 고농도로 생산하는 것은 스트렙토미세스 속 균주를 배양하여 항생물질을 생산하는 통상의 방법에 의하여 배양배지에 엘-메티오닌을 첨가하여 실시할 수 있다.The high concentration of adriamycin by culturing the strain according to the method of the present invention can be carried out by adding L-methionine to the culture medium by a conventional method of culturing Streptomyces sp.
배지에 첨가되는 엘-메티오닌의 양은 1-32g/ℓ의 범위이며, 첨가시기는 배양 초기 또는 배양 도중에 첨가하여도 무방하다.The amount of el-methionine added to the medium is in the range of 1-32 g / l, and the addition time may be added at the beginning or during the culture.
상기와 같이 배지에 엘-메티오닌을 첨가하여 배양을 실시하면 첨가하지 않은 경우에 비하여 생산성이 약 17% 정도로 향상된다.As described above, when cultured by adding L-methionine to the medium, the productivity is improved by about 17% compared with the case without addition.
이하 실시예에 의해 본 발명을 보다 상세히 설명하지만 본 발명이 이들 실시예에 의해 제한되는 것은 아니다.The present invention will be described in more detail with reference to the following Examples, but the present invention is not limited to these Examples.
[참고예 1]Reference Example 1
친주인 스트렙토미세스 퓨세티우스 바. 카에시우스 ATCC 27952를 한천 사면배지(자당 20g/ℓ, 건조효모 1g/ℓ, 인산 제2수소칼륨 2g/ℓ, 질산나트륨 2g/ℓ, 황산마그네슘 2g/ℓ, 한천 20g/ℓ)에서 10-12일간 배양하고 생성된 포자를 10ml의 식염수에 현탁 후 초음파(Branson 5200)를 30초간 조사하고 탈지면으로 여과하여 포자현탁액을 획득하였다.Parent, Streptomyces fuseotius bar. Caesius ATCC 27952 in agar agar medium (20g / l sucrose, 1g / l dry yeast, 2g / l potassium dihydrogen phosphate, 2g / l sodium nitrate, 2g / l magnesium sulfate, 20g / l agar) After culturing for 12 days, the resulting spores were suspended in 10 ml of saline solution, irradiated with ultrasound (Branson 5200) for 30 seconds, and filtered through cotton wool to obtain a spore suspension.
획득한 현탁액을 식염수로 세척 후 450 ㎍/ml의 NTG(N-메틸-N-니트로-니트로소구아니딘)를 이용하여 28℃에서 1시간동안 처리하여 변이를 일으킨 후 엘-메티오닌 유사체로서 셀레노-메티오닌이 약 20㎍/ml 함유된 배지에 도말하여 5-10일간 28℃에서 배양하여 생육 가능한 변이주를 분리하였다.The resulting suspension was washed with brine and then treated with 450 μg / ml of NTG (N-methyl-N-nitro-nitrosoguanidine) at 28 ° C. for 1 hour to cause mutations followed by seleno- as an el-methionine analog. Variants were grown on medium containing about 20 μg / ml methionine and incubated at 28 ° C. for 5-10 days to grow viable strains.
분리된 엘-메티오닌 유사체에 대한 내성을 가진 변이주들을 상기와 동일한 배지에서 배양하여 아드리아마이신 고생산 균주들을 선별하고 이들 변이주에게 셀레노-메티오닌의 농도를 조금씩 증가한 배지에서 계대배양하여 내성도가 증가된 변이주를 선별하므로써 아드리아마이신을 고농도로 축적하는 변이주 MWA-72를 선별하였다.Mutants with resistance to the isolated L-methionine analogs were cultured in the same medium to select high adriamycin strains and passaged in medium in which the concentrations of seleno-methionine were gradually increased to these strains. The mutant strain MWA-72 was screened by screening mutant strains for high concentrations of adriamycin.
상기와 같이 하여 얻은 변이주 스트렙토미세스 퓨세티우스 바. 카에시우스 MWA-72는 사단법인 한국 종균협회에 1993년 11월 9일자로 수탁번호 KFCC-10798로 기탁되어 있다.Mutant strain Streptomyces fuseotius bar obtained as described above. Kaesius MWA-72 has been deposited with Accession No. KFCC-10798 dated 9 November 1993 to the Korean spawn association.
[실시예 1]Example 1
한천 사면배지(자당 20g/ℓ, 건조효모 1g/ℓ, 인산 제2수소칼륨 2g/ℓ, 질산나트륨 2g/ℓ, 황산마그네슘 2g/ℓ, 한천 20g/ℓ)에서 10-12일 배양한 엘-메티오닌 유사체 내성변이주 MWA-72(KFCC-10798)를 종균배지(포도당 10g/ℓ, 펩톤 6g/ℓ, 효모추출물 5g/ℓ, 탄산칼슘 3g/ℓ, 황산마그네슘 0.5g/ℓ, pH 7.0) 50ml가 함유된 500ml 삼각 플라스크에 1백금이씩 식균하여 28℃에서 회전진탕기(200rpm)를 사용하여 2일간 종배양한 후 이 종배양액을 하기 표 1에 나타낸 각종 아미노산이 첨가된 발효배지(자당 50g/ℓ, 포도당 20g/ℓ, 대두분 30g/ℓ, 인산 제2칼륨 1g/ℓ, 황산마그네슘 0.5g/ℓ, 탄산칼슘 4g/ℓ, 황산 제1철 0.01g/ℓ, 황산 아연 0.01g/ℓ, 황산구리 0.01g/ℓ, 황산코발트 0.01g/ℓ, pH) 50ml가 함유된 500ml 삼각 플라스크에 5ml씩 식균하여 28℃에서 흰전진탕기(250rpm)를 이용하여 7일간 본배양하였다. 발효완료액의 정량분석은 HPLC를 이용하여였으며 발효액의 전처리를 위하여 발효액 1ml에 에탄올 2ml를 첨가하고 55℃에서 1시간동안 방치한 후 원심분리하여 상등액을 취하였다. 이 액 10㎕씩을 후술하는 조건의 HPLC로 분석하고 각종 아미노산의 첨가에 따른 아드리아마이신의 생성량을 표 1에 나타내었다.L-cultured for 10-12 days in agar agar medium (20g / l sucrose, 1g / l dry yeast, 2g / l potassium dihydrogen phosphate, 2g / l sodium nitrate, 2g / l magnesium sulfate, 20g / l agar) 50 ml of seed culture medium (glucose 10g / l, peptone 6g / l, yeast extract 5g / l, calcium carbonate 3g / l, magnesium sulfate 0.5g / l, pH 7.0) was added to methionine analogue resistant strain MWA-72 (KFCC-10798). Platinum was inoculated in a 500 ml Erlenmeyer flask containing 2 hours of seed culture at 28 ° C. using a rotary shaker (200 rpm), followed by fermentation broth with various amino acids shown in Table 1 (50 g / sucrose). l, glucose 20 g / l, soybean meal 30 g / l, potassium diphosphate 1 g / l, magnesium sulfate 0.5 g / l, calcium carbonate 4 g / l, ferrous sulfate 0.01 g / l, zinc sulfate 0.01 g / l, 5 ml each of the 500 ml Erlenmeyer flask containing 0.01 g / l copper sulfate, 0.01 g / l cobalt sulfate, and pH 50 ml was inoculated, and main culture was carried out using a white shaker (250 rpm) at 28 ° C. for 7 days. The quantitative analysis of the fermentation broth was performed using HPLC. For pretreatment of the fermentation broth, 2 ml of ethanol was added to 1 ml of the fermentation broth, and the mixture was left at 55 ° C. for 1 hour, followed by centrifugation to obtain a supernatant. Each 10 μl of this solution was analyzed by HPLC under the following conditions, and the amounts of adriamycin produced by the addition of various amino acids are shown in Table 1.
[HPLC 분석조건][HPLC Analysis Conditions]
컬 럼 : μ-본다팩(Bondapack) C18(5㎛), 30cm×3.9cmColumn: μ-Bondapack C18 (5㎛), 30cm × 3.9cm
이동상 : 0.1% 인산-메탄올(25/75)Mobile phase: 0.1% phosphate-methanol (25/75)
유 속 : 1.5ml/minFlow rate: 1.5ml / min
검 출 : UV 254nmDetection: UV 254nm
[실시예 2]Example 2
실시예 1과 동일한 조건하에 실시하되, 엘-메티오닌의 농도를 표 2와 같이 변화시켜 배양하고, 아드리아마이신의 생성량을 측정하여 결과를 표 2에 나타내었다.It was carried out under the same conditions as in Example 1, but incubated by changing the concentration of L-methionine as shown in Table 2, and measured the amount of adriamycin production is shown in Table 2.
[실시예 3]Example 3
실시예 1과 동일한 조건에서 실시하되, 배양중 엘-메티오닌을 배양 시간별로 첨가하여 아드리아마이신을 생성시키고, HPLC에 의해 아드리아마이신의 생성량을 측정하고 결과를 표 3에 나타내었다.It was carried out under the same conditions as in Example 1, but during the incubation of the addition of el-methionine by incubation time to generate adriamycin, the amount of adriamycin produced by HPLC was measured and the results are shown in Table 3.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019930024430A KR970002493B1 (en) | 1993-11-17 | 1993-11-17 | Process for preparing adriamycin by fermentation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019930024430A KR970002493B1 (en) | 1993-11-17 | 1993-11-17 | Process for preparing adriamycin by fermentation |
Publications (2)
Publication Number | Publication Date |
---|---|
KR950014313A KR950014313A (en) | 1995-06-15 |
KR970002493B1 true KR970002493B1 (en) | 1997-03-05 |
Family
ID=19368242
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019930024430A KR970002493B1 (en) | 1993-11-17 | 1993-11-17 | Process for preparing adriamycin by fermentation |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR970002493B1 (en) |
-
1993
- 1993-11-17 KR KR1019930024430A patent/KR970002493B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
KR950014313A (en) | 1995-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4970198A (en) | Antitumor antibiotics (LL-E33288 complex) | |
US5108912A (en) | Antitumor antibiotics (LL-E33288 complex) | |
Yoshimoto et al. | New anthracycline metabolites from mutant strains of Streptomyces galilaeus MA144-M1 I. Isolation and characterization of various blocked mutants | |
KR970002493B1 (en) | Process for preparing adriamycin by fermentation | |
EP0050724B1 (en) | Process for anthracycline glycosides | |
CA2088667A1 (en) | Process for producing astaxanthin by fermentation | |
KR100356614B1 (en) | New Microorganisms and Manufacturing Methods Thereof | |
EP0275966B1 (en) | A doxorubicin derivative, a process for preparing the same, pharmaceutical preparations comprising the same, and the use of the same for the manufacture of useful medicaments | |
KR100422307B1 (en) | Microorganism producing riboflavin and production method of riboflavin using thereof | |
KR100344018B1 (en) | 5'-Xanthylic acid producing microorganism | |
KR100536676B1 (en) | A process for the biotransformation of colchicone compounds into the corresponding 3-glycosyl derivatives | |
EP0050725A1 (en) | Process for aclacinomycins and microorganism used therein | |
US4673645A (en) | Process and microorganisms for producing mitomycin A by fermentation | |
US4592999A (en) | Process for producing daunomycin | |
KR960014621B1 (en) | Streptomyces lavendofoliae dk-506, and processing method of aclacinomycin-a | |
KR970000591B1 (en) | New strain of streptomyces lavendofoliae dkrs and preparation of aclacinomycin a,b and y and glycon using the same | |
FI90566B (en) | Microbiological method for production of 4'-13(S)-dihydro- 4'-iododoxorubicin | |
Kim et al. | Improved production, and purification of aclacinomycin A from Streptomyces lavendofoliae DKRS | |
KR960016591B1 (en) | New antitumor agent obtained by microbial streptoselective reduction of 4'-deoxy-4'-iododoxorubicin | |
KR100429926B1 (en) | Microorganism overproducing 5’-xanthylic acid | |
KR19990050233A (en) | Mutant strains producing anthracycline antibiotics and methods of producing toxin rubicin by mixing and culturing them | |
KR100197865B1 (en) | Inhibitors against tyrosinase activity and melanin formation | |
AU601857B2 (en) | A new antitumor agent obtained by microbial stereoselective reduction of 4'-deoxy-4'-iododoxorubicin | |
KR910007819B1 (en) | Microorganism for producing streptokiuas & screptodprnase | |
KR20200091580A (en) | Method for producing vancomycin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
G160 | Decision to publish patent application | ||
E701 | Decision to grant or registration of patent right | ||
NORF | Unpaid initial registration fee |